Conference

Aspen Neuroscience to Showcase Advances in Autologous Cell Therapy Development at 2024 Cell & Gene Meeting on the Mesa

by
Untitled design 16 e1736137671761

SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences

by
Aspen Kameel Farag IMG 7524 Final e1727705111641

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. About Aspen Neuroscience Aspen Neuroscience, Inc., headquartered in San Diego, is dedicated to autologous regenerative medicine. The company’s … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

by
ClearPoint Filming Team

SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27 … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona

by
wpc2023 logo color scaled

SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions

by
Andres ISSCR

SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass. His presentation will cover experiences … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

The new news in stem cell research

by

DEC 1, 2017 – PRESENTATION Empowerment Day 2017 – Parkinson’s Association of San Diego, San Diego, CA, USA

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

GENOMICS FOR STEM CELL-BASED THERAPIES

by

MAR 14-15, 2019 – PRESENTATIONFuture of Individualized Medicine – Scripps Research, La Jolla, CA, USA

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved